Recommendation of the President – PET/MRI

On 31 May 2022 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation:

Recommendation No. 51/2022 of 31 May 2022 of the President of the Agency for Health Technology Assessment and Tariff System on the legitimacy of changing medical technology for the health care services of Positron Emission Tomography concerning simultaneous positron emission tomography and magnetic resonance imaging (PET/MRI) with 18F fluorodeoxyglucose for oncology indications.

Publication in Public Information Bulletin (BIP)